Nabriva Therapeutics AG Analysis
| Analyst Ratings |
|
Average Target Price
|
8.00
|
|
Average Rating
|
2.50
|
|
# Strong Buys
|
0
|
|
# Buys
|
0
|
|
# Holds
|
1
|
|
# Sells
|
1
|
|
# Strong Sells
|
0
|
| Quarterly Earnings History |
| Quarter |
EPS Estimate |
EPS Actual |
EPS Difference |
Surprise Percent |
|
2023-03-31
|
-3.25
|
0.00
|
3.25
|
100.00%
|
|
2022-12-31
|
-3.68
|
0.00
|
3.68
|
100.00%
|
|
2022-09-30
|
-4.03
|
-4.21
|
-0.18
|
-4.47%
|
|
2022-06-30
|
-5.00
|
-4.50
|
0.50
|
10.00%
|
|
2022-03-31
|
-4.75
|
-5.00
|
-0.25
|
-5.26%
|
|
2021-12-31
|
-4.75
|
-6.00
|
-1.25
|
-26.32%
|
|
2021-09-30
|
-6.12
|
-0.52
|
5.60
|
91.50%
|
|
2021-06-30
|
-8.67
|
-7.25
|
1.42
|
16.38%
|
| Annual Earnings History |
| Fiscal Year End |
EPS |
|
2022-12-31
|
-13.71
|
|
2021-12-31
|
-27.02
|
|
2020-12-31
|
-54.15
|
|
2019-12-31
|
-11.20
|
|
2018-12-31
|
-5.80
|
|
2017-12-31
|
-2.50
|
|
2016-12-31
|
-2.75
|